Cor Vasa 2024, 66(5):529-533 | DOI: 10.33678/cor.2024.066

(Complex treatment and its complications in a patient with hypertrophic cardiomyopathy)

Zuzana Holubcováa, Matej Strýčeka, Rostislav Polášeka, b, Pavol Tomašova, b
a Kardiocentrum, Krajská nemocnice Liberec, Liberec, Česká republika
b Fakulta zdravotnických studií, Technická univerzita v Liberci, Liberec, Česká republika

Hypertrophic cardiomyopathy is a genetic disorder characterized by increased left ventricle thickness greater than 15 milimetres in the absence of any other explanatory cause. The diagnostics and treatment of patients with hypertrophic cardiomyopathy include search for a management of left ventricular outflow tract obstruction, risk stratification for sudden cardiac death and genetic testing and screening of family members. This case report describes a young man with a chronic skin disease on permanent biological therapy who had a family history of sudden cardiac death and had recently been diagnosed with hypertrophic cardiomyopathy with symptomatic left ventricular outflow tract obstruction. An alcohol septal ablation had been indicated, resulting in improved hemodynamic and clinical outcome. An implantable cardioverter-defibrillator was implanted for the primary prevention of sudden cardiac death. However, an early device pocket infection due to the patient's skin disease and the development of reactive pericarditis led to complications.

Keywords: Hypertrophic cardiomyopathy, Septal reduction therapy, Sudden death

Received: April 15, 2024; Revised: April 15, 2024; Accepted: August 26, 2024; Prepublished online: June 2, 2012; Published: October 25, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Holubcová Z, Strýček M, Polášek R, Tomašov P. (Complex treatment and its complications in a patient with hypertrophic cardiomyopathy). Cor Vasa. 2024;66(5):529-533. doi: 10.33678/cor.2024.066.
Download citation

References

  1. Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2020;142:e558-e631. Go to original source... Go to PubMed...
  2. Arbelo E, Protonotarios A, Gimeno JR, et al.; ESC Scientific Document Group. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J 2023;44:3503-3626. Go to original source... Go to PubMed...
  3. Elliott P, McKenna WJ. Hypertrophic cardiomyopathy. Lancet 2004;363:1881-1891. Go to original source... Go to PubMed...
  4. Cardim N, Freitas A, Brito D. From hypertrophic cardiomyopathy centers to inherited cardiovascular disease centers in Europe. A small or a major step? A position paper from the Nucleus of the Working Group on Myocardial and Pericardial Diseases of the Portuguese Society of Cardiology. Rev Port Cardiol 2011;30:829-835. Go to original source... Go to PubMed...
  5. Cardim N, Galderisi M, Edvardsen T, et al. Role of multimodality cardiac imaging in the management of patients with hypertrophic cardiomyopathy: an expert consensus of the European Association of Cardiovascular Imaging Endorsed by the Saudi Heart Association. Eur Heart J Cardiovasc Imaging 2015;16:280. Go to original source... Go to PubMed...
  6. Mathai S, Williams L. Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy and the impact of mavacamten. Ther Adv Chronic Dis 2022;13:20406223221136074. Go to original source... Go to PubMed...
  7. Dimitrow PP, Bober M, Michalowska J, Sorysz D. Left ventricular outflow tract gradient provoked by upright position or exercise in treated patients with hypertrophic cardiomyopathy without obstruction at rest. Echocardiography 2009;26:513-520. Go to original source... Go to PubMed...
  8. Leonardi RA, Kransdorf EP, Simel DL, Wang A. Meta-analyses of septal reduction therapies for obstructive hypertrophic cardiomyopathy: comparative rates of overall mortality and sudden cardiac death after treatment. Circ Cardiovasc Interv 2010;3:97-104. Go to original source... Go to PubMed...
  9. Veselka J, Krejčí J, Tomašov P, et al. Outcome of patients after alcohol septal ablation with permanent pacemaker implanted for periprocedural complete heart block. Int J Cardiol 2014;171:e37-e38. Go to original source... Go to PubMed...
  10. O'Mahony C, Jichi F, Pavlou M, et al. Hypertrophic cardiomyopathy outcomes I. A novel clinical riskprediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J 2014;35:2010-2020. Go to original source... Go to PubMed...
  11. Aziz S, Leon AR, El-Chami MF. The subcutaneous defibrillator: a review of the literature. J Am Coll Cardiol 2014;63: 1473-1479. Go to original source... Go to PubMed...
  12. Murphy SL, Anderson JH, Kapplinger JD, et al. Evaluation of the Mayo Clinic phenotype-based genotype predictor score in patients with clinically diagnosed hypertrophic cardiomyopathy. J Cardiovasc Transl Res 2016;9:153-161. Go to original source... Go to PubMed...

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.





Cor et Vasa

You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.